Results 191 to 200 of about 249,247 (291)

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1205-1215, May 2026.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco, Troy D. Wood, Raymond Cha, Jill S. Hochreiter, Susan L. Rosenkranz, Mona Farhad, Kyle R. Whitson, Connor E. Gould, Lauren E. Hill, Linda L. Hale, Philip H. Lindhorst, Diala Ghazal, Charlene R. Taylor, Madiha Quraishi, Suzanne M. Siminski, Yoninah Cramer, Heather L. Sprenger, Gene D. Morse   +17 more
wiley   +1 more source

Protocol for purifying recombinant HBV capsids from HepG2 cells and comparative phosphorylation analysis by phosphate-affinity SDS-PAGE. [PDF]

STAR Protoc
Culhane K, Kumar S, Hu J, Wang JC.
europepmc   +1 more source

Salt in the Wound: Assessing Pathogen Susceptibility in Amphibian Populations Across a Gradient of Salt Pollution

Ecology and Evolution, Volume 16, Issue 5, May 2026.
The survival function of nine larval wood frog populations and their viral loads when exposed to FV3. The populations were collected as eggs from a range of salt‐polluted ponds. Viral load data are means ±1 SE. The populations are ordered in terms of the saltiness of their natal ponds.
Rick A. Relyea, Jason T. Hoverman, Jessica Hua, Devin K. Jones, Melissa Lech, Brian Mattes, Candace Schermerhorn, Bryon Tuthill, Isabela Tuthill   +8 more
wiley   +1 more source

The host protein cyclophilin A restricts nuclear entry of HIV-1 mutants by reducing the elasticity of the viral capsid. [PDF]

PLoS Pathog
Hong J, Deshpande A, Thakare Y, Simonovsky L, Douglas AW, Guinness CM, Rotem-Dai N, Kortyna ML, Klarhof JO, Shi J, James LC, Boecking T, Francis AC, Rousso I, Aiken C.   +14 more
europepmc   +1 more source

Evaluation of Relative Bioavailability and Food Effect of a Fixed‐Dose Combination Tablet of Islatravir and Lenacapavir

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Long‐acting oral HIV‐1 treatments can potentially reduce pill burden, treatment fatigue, suboptimal adherence, and treatment failure. A combination of islatravir, a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a capsid inhibitor, is being investigated as a weekly oral HIV‐1 treatment.
Jing Niu, Haeyoung Zhang, John Ling, Sharline Madera, Nerissa Kwok, Steve West, Diane Longo, Gillian Gillespie, Cyril Llamoso, Dhananjay D. Marathe   +9 more
wiley   +1 more source

Structural and phylogenetic analyses of umbravirus and umbra-like virus genomes suggest evolution of capsid-like proteins from 30K movement proteins. [PDF]

J Virol
Simon AE, Needham JM, Mikkelsen A, Atallah O.   +3 more
europepmc   +1 more source

Liver Gene Therapy in Fabry Disease Mice With Low Doses of rAAV2/8 Expressing a Codon‐Optimized hGLA cDNA Results in Long‐Term Disease Correction

Journal of Inherited Metabolic Disease, Volume 49, Issue 3, May 2026.
AAV‐mediated gene therapy targets the liver to produce and secrete into circulation functional α‐Gal A, which is taken up by tissues to reduce glycosphingolipid accumulation and prevent disease progression in juvenile Fabry mice, even at low AAV doses. ABSTRACT Fabry disease (FD) is an X‐linked lysosomal storage disorder caused by mutations in the GLA ...
Himanshi Saxena, Rossana Domenis, Giulia Romano, Jessica Biasizzo, Martina Ferro, Dania Ferino, Antonio Vicidomini, Alessandra Iaconcig, Giulia Bortolussi, Lorena Zentilin, Andrea Dardis, Andrés F. Muro   +11 more
wiley   +1 more source

Host restriction factors and p17-Driven inflammaging in HIV-1: From molecular pathogenesis to functional cure. [PDF]

AIMS Microbiol
Nitsotolis T, Assimakopoulos SF, Kouriannidi E, Lagadinou M, Papalexandrou A, Ioannou P, Marangos M, Milionis H, Christaki E.   +8 more
europepmc   +1 more source

HIV capsid protein [PDF]

Science-Business eXchange, 2011
openaire   +1 more source

Detection of gas bubbles and local voids in molecular simulations using burbuja

Protein Science, Volume 35, Issue 5, May 2026.
Abstract We present burbuja (Baring Unseen Regions of Bubbles Using Joint‐Density Analysis), an automated software tool for detecting and characterizing gas bubbles and other local voids in molecular structures and trajectories containing explicit aqueous solvent. We describe the burbuja algorithm and demonstrate its accuracy and utility across a range
Abraham Muñiz‐Chicharro, Lane W. Votapka, Rommie E. Amaro   +2 more
wiley   +1 more source